New chemo cocktails aim to save eyes in kids with retinoblastoma

NCT ID NCT02866136

Ongoing Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests different chemotherapy regimens in 133 children with retinoblastoma, a rare eye cancer. The goal is to shrink tumors and avoid removing the eye or using radiation. Treatments include intravenous and intra-arterial chemotherapy, sometimes combined with laser therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (etoposide, carboplatin, melphalan, vincristine)
What this could lead to: If successful, this could offer effective eye-sparing treatments for children with retinoblastoma, reducing the need for eye removal or radiation.
What could go wrong: This is a mid-stage trial with no control group, so results are preliminary. Chemotherapy has significant side effects, and not all children may respond well.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDREN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retina neoplasm retinal cancer retinoblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHILDREN RETINAL NEOPLASM RETINOBLASTOMA

Contacts and locations

Show contact details

Locations

Institut Curie

Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.